CONTENTS

List of Abbreviations 6

Chapter 1  General Introduction 7

Chapter 2  Measuring Inflammatory Activity 25

  2.1 The Distribution of New Enhancing Lesion Counts in Multiple Sclerosis: Further Explorations 27
  2.2 T2w Subtraction MR Imaging in Phase II MS Trials: A Powerful New Outcome Measure 43
  2.3 Cumulative Enhancing Lesion Volume as Outcome Measure in MS Clinical Trials 63

Chapter 3  Measuring Neuroprotection and Neurorepair 77

  3.1 Persistent T1 Hypointensity as an MRI Marker for Treatment Efficacy in Multiple Sclerosis 79
  3.2 Cerebral Atrophy as Outcome Measure in Short-term Phase 2 Clinical Trials in Multiple Sclerosis 93
  3.3 Lesional Magnetization Transfer Ratio — a Feasible Outcome for Remyelinating Treatment Trials in MS 107

Chapter 4  General Discussion, Summary, and Future Perspectives 127

Chapter 5  Summary in Dutch (Nederlandse samenvatting) 145

Dankwoord 151

Curriculum Vitae 157